Which is the best combination therapy in relapsed and refractory multiple myeloma?
Can we cure 50% of all multiple myeloma patients in the next five years?
How can MRD and disease be assessed in routine practice?
Features of high-risk multiple myeloma and how to treat it
The role of proteasome inhibitors in multiple myeloma